IGRA tests perform similarly to TST but cause no adverse reactions: pediatric experience in Finland

BMC Res Notes. 2009 Jan 15;2:9. doi: 10.1186/1756-0500-2-9.


Background: Two commercial interferon gamma release assays (IGRAs) (QuantiFERON(R)-TB Gold in Tube and T SPOT(R)-TB) to detect a contact with M. tuberculosis have recently become available. The majority of studies agree that the sensitivity and specificity of these methods are superior to the Tuberculin Skin Tests (TSTs) in detecting an exposure to bacteria in latently infected individuals and in clinical tuberculosis. However, the data in children remains limited.

Findings: Consecutively collected samples from children (n = 99) representing age range from zero to 18 years were analyzed in a retrospective non-blinded study. The two IGRAs were modified and adapted to the needs of Finland, a country of a low tuberculosis incidence. For 27 children, both tests were performed simultaneously and compared with the TST and clinician's diagnosis. The sensitivity, specificity, and accuracy of both IGRAs was determined. QuantiFERON TB Gold and T SPOT-TB performed (respectively) as follows: sensitivities 0.92 (95% confidence interval, CI, 0.67-0.99) and 0.85 (0.64-0.95); specificities 0.91 (0.77-0.97) and 1.00 (0.93-1.00); accuracies 0.91 (0.80-0.97) and 0.96 (0.88-0.99). This compares favorably to the TST whose known figures are 0.90, 0.95, and 0.95, respectively. The agreement between the IGRAs was high, k = 0.89. Finally, both methods agreed well with the TST, k = 0.86 for TST/QuantiFERON-TB Gold and k = 0.76 for TST/T SPOT-TB.

Conclusion: The sensitivity and specificity of IGRA methods compares well with the TST without the inconveniences and complications associated with TST, including exaggerated delayed type hypersensitivity reactions. These properties place them as acceptable substitutes for TST.